Want to see CGTX full AI Analyst Report?
CGTX Stock Chart & Stats
$1.19
-$0.03(-3.56%)
At close: 4:00 PM EST
$1.19
-$0.03(-3.56%)
Day’s Range― - ―
52-Week Range$0.55 - $3.83
Previous CloseN/A
Volume950.02K
Average Volume (3M)2.91M
Market Cap
$85.99M
Enterprise Value$36.98
Total Cash (Recent Filing)$31.13M
Total Debt (Recent Filing)$465.00K
Price to Earnings (P/E)―
Beta2.69
Next Earnings
Aug 11, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding89,498,020
10 Day Avg. Volume2,171,776
30 Day Avg. Volume2,911,286
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.87
Price to Sales (P/S)0.00
P/FCF Ratio-4.00
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.50Price Target Upside194.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.28
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageExtremely low debt and a positive equity base reduce interest and refinancing pressure, giving the company structural financial optionality. This durable strength limits bankruptcy risk and preserves flexibility to fund development or partner programs without immediate reliance on costly debt.
Regulatory Path ProgressA constructive FDA interaction that clarifies trial design and endpoints materially reduces regulatory uncertainty. Over months, that makes a registrational Phase 3 pathway more executable, improving the odds that clinical investment can translate into a viable approval strategy and commercial opportunity.
Clinical Efficacy Signals & Funded TrialRobust Phase 2 efficacy signals in DLB and a grant-funded Alzheimer’s Phase 2 lower technical and near-term financing risk. Durable benefits include a clearer clinical value proposition for zervimesine and reduced cash burden for one program, supporting longer-term development continuity.
Bears Say
Pre-Revenue ProfileNo product revenue and sustained operating losses mean the business cannot self-fund development. Over the medium term this creates recurring dependence on external capital, increasing dilution risk and making long-term program execution contingent on successful financings or partnerships.
Negative Free Cash FlowPersistent negative FCF of roughly -$20M TTM, despite improvement, indicates ongoing cash outflows for R&D. Structurally this necessitates periodic capital raises or collaborations, which can delay programs or dilute shareholders if market conditions tighten over the next several quarters.
Equity Erosion & Negative ROEA shrinking equity base and deeply negative ROE reflect value erosion from continued losses. Over months this undermines the company’s capital cushion, raises the likelihood of dilutive financings, and reduces resilience to clinical or regulatory setbacks that would require further funding.
Cognition Therapeutics News
CGTX FAQ
What was Cognition Therapeutics’s price range in the past 12 months?
Cognition Therapeutics lowest stock price was $0.55 and its highest was $3.83 in the past 12 months.
What is Cognition Therapeutics’s market cap?
Cognition Therapeutics’s market cap is $85.99M.
When is Cognition Therapeutics’s upcoming earnings report date?
Cognition Therapeutics’s upcoming earnings report date is Aug 11, 2026 which is in 21 days.
How were Cognition Therapeutics’s earnings last quarter?
Cognition Therapeutics released its earnings results on May 07, 2026. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.068 by $0.018.
Is Cognition Therapeutics overvalued?
According to Wall Street analysts Cognition Therapeutics’s price is currently Undervalued.
Does Cognition Therapeutics pay dividends?
Cognition Therapeutics does not currently pay dividends.
What is Cognition Therapeutics’s EPS estimate?
Cognition Therapeutics’s EPS estimate is -0.06.
How many shares outstanding does Cognition Therapeutics have?
Cognition Therapeutics has 89,498,020 shares outstanding.
What happened to Cognition Therapeutics’s price movement after its last earnings report?
Cognition Therapeutics reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.068. Following the earnings report the stock price went up 4.31%.
Which hedge fund is a major shareholder of Cognition Therapeutics?
Currently, no hedge funds are holding shares in CGTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cognition Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.50 (194.12% Upside)
$3.50 (194.12% Upside)
Hedge Fund Trend
Decreased
By 151.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $32.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
291.01%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
53.79%
Trailing 12-Months
Company Description
Cognition Therapeutics
Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advanced experimental therapy is CT1812, which acts as a sigma-2 receptor antagonist. This compound is currently being evaluated in Phase II clinical trials for the management of mild-to-moderate Alzheimer's disease and dementia with Lewy bodies (DLB). Additionally, it has successfully concluded Phase I trials for early-stage Alzheimer's and is undergoing preclinical investigation for dry age-related macular degeneration (AMD). The company's pipeline also includes CT2168, a treatment candidate for synucleinopathies—a category of diseases encompassing DLB and Parkinson's disease—and CT2074, which is in development for dry AMD. Cognition Therapeutics, Inc. was established in 2007 and operates from its headquarters in Purchase, New York.
CGTX Stock 12 Month Forecast
Average Price Target
$3.50
▲(194.12% Upside)
Technical Analysis
Tonix Pharma
―
Adicet Bio
―
Milestone Pharmaceuticals
―
Elicio Therapeutics
―
Alto Neuroscience, Inc.
―
Ownership Overview
10.81% Insiders
4.31% Mutual Funds
0.06% Other Institutional Investors
80.75% Public Companies and
Individual Investors